Loading organizations...
SynBioVen is a specialized investment vehicle, deploying pre-seed and seed funding into early-stage synthetic biology startups. The firm provides capital alongside strategic mentorship from its experienced team, covering scientific research, business development, and finance. Portfolio companies also gain access to R&D facilities like the London Biofoundry.
Co-founded in early 2022 by Paul Freemont, a distinguished professor and SynbiCITE co-director, SynBioVen's leadership includes Sir David Harding and Lord David Willetts. The firm was built on the conviction that synthetic biology will drive the next industrial revolution and the transition to a net-zero economy.
SynBioVen supports innovative synthetic biology companies developing solutions across diverse fields, from sustainable manufacturing to medical therapeutics. The firm envisions UK-based synthetic biology enterprises achieving global leadership in the bioeconomy, translating scientific innovations into impactful commercial products addressing critical global challenges.
SynBioVen has 4 tracked investments across 4 companies. The latest tracked deal is $8.1M Series A in Resurrect Bio in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 17, 2026 | Resurrect Bio | $8.1M Series A | TOM Greene | AgFunder, Calculus Capital, Pymwymic, UK Innovation & Science Seed Fund |
| May 5, 2025 | Solena Materials | $6.7M Seed | — | David Harding, Insempra |
| Jan 20, 2023 | Multus | $11.5M Grant / Series A | Julio Benetti | Asahi Kasei, BIG Idea Ventures, Innovate UK, SOSV |
| Nov 1, 2022 | Eden Bio | $1.0M Seed | Synbioven | 7percent Ventures, Dragonfly Capital, Hack VC, Meta Change Capital, #secretfund, Unruly Capital, Spencer Noon, XAnge, Didier Valet, Ernest Oppetit, Fernando Martinelli, Frederic Montagnon, Itamar Lesuisse, John Lilic, Julien Romanetto, Nicolas Debock, Nicolas Steegmann, Andy Russell, Kevin Mascarenhas, Noor Shaker, Stefano Bernardi, Dhyan Capital, Saras Capital |
